Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Japan's Meiji Holdings says drug unit started late-stage trial for COVID vaccine

FILE PHOTO: The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

Japan's Meiji Holdings Co said on Tuesday its drug subsidiary had started a Phase III trial of an mRNA-based vaccine for COVID-19.

Meiji Seika Pharma had started the late-stage trial among 780 subjects in Japan, with the test period running from November to April 2024, Meiji said in a statement.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.